Sesen Bio reports data update from phase 3 trial for highrisk nonmuscle invasive bladder cancer

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive

More From BioPortfolio on "Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer"